Venmax Drugs & Pharmaceuticals Share Price | Venmax Drugs & Pharmaceuticals Stock Screener
VENMAX
Pharmaceuticals
Share Price BSE
₹23.21
▼
-0.15 (-0.64%)
As of May 20, 2026, the Venmax Drugs & Pharmaceuticals share price (BSE: VENMAX) is ₹23.21, down 0.64% from the previous close, with shares trading between ₹22.61 and ₹24.99, and a 52-week range of ₹20.15–₹35.29.
Check VENMAX 52-week high low for the annual price range and momentum.
Use the Venmax Drugs & Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Venmax Drugs & Pharmaceuticals Market Cap
₹29.35 Cr.
VENMAX P/E Ratio (TTM)
33.68
Venmax Drugs & Pharmaceuticals P/B Ratio
1.86
EPS (TTM)
₹-0.02
Dividend Yield
-
Debt to Equity
0.11
VENMAX 52 Week High
₹35.29
Venmax Drugs & Pharmaceuticals 52 Week Low
₹20.15
Operating Margin
-131.00%
Profit Margin
-
VENMAX Revenue (TTM)
₹2.00
EBITDA
-
Net Income
-
Total Assets
₹16.00
Total Equity
₹14.00
Venmax Drugs & Pharmaceuticals Share Price Chart
Screen Venmax Drugs & Pharmaceuticals share price with an interactive chart. Analyse VENMAX price trends and volatility across different timeframes.
Venmax Drugs & Pharmaceuticals Company Profile - Fundamental Screener
Screen Venmax Drugs & Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for VENMAX shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE154G01022
Venmax Drugs & Pharmaceuticals Balance Sheet Screener
Screen VENMAX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 16 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Current Assets | 16 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 14 | 4 | -1 | -1 | -1 | -3 | -3 | -2 | -2 | -2 |
| Share Capital | 12 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 3 | -6 | -6 | -6 | -6 | -8 | -8 | -8 | -7 | -7 |
Venmax Drugs & Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Venmax Drugs & Pharmaceuticals income statement and profit fundamentals.
Analyze VENMAX quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Venmax Drugs & Pharmaceuticals share price evaluation.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 2 |
| Expenses | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 3 |
| EBITDA | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Operating Profit % | -131.00% | 0.00% | 0.00% | 0.00% | -198.00% | -54.00% | -158.00% | 0.00% | -238.00% | -7.00% | -5.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| EPS | -0.02 | 0.12 | 0.43 | 3.52 | -0.31 | -0.52 | -0.45 | -0.46 | -2.55 | -0.26 | -0.15 |
Venmax Drugs & Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen VENMAX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | -1 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Activities | 5 | 0 | 0 | -2 | 0 | 0 | 0 | 0 | 1 | 0 |
| Net Cash Flow | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Venmax Drugs & Pharmaceuticals Shareholding Pattern Screener
See Venmax Drugs & Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Venmax Drugs & Pharmaceuticals promoter holding and ownership changes for VENMAX on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 13.80% | 15.14% | 23.14% | 23.14% | 23.14% | 23.14% | 23.14% | 23.14% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.15% | 0.15% | 0.15% | 0.15% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 66.29% | 64.25% | 65.36% | 65.01% | 65.24% | 65.54% | 65.67% | 65.66% |
| Other Holding | 19.91% | 20.61% | 11.51% | 11.86% | 11.47% | 11.17% | 11.04% | 11.06% |
| Shareholder Count | 6,802 | 6,815 | 6,764 | 6,729 | 6,756 | 6,657 | 6,291 | 6,252 |
Venmax Drugs & Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Venmax Drugs & Pharmaceuticals dividend history with payout and yield data.
View Venmax Drugs & Pharmaceuticals dividend details including ex-dates and amounts for VENMAX stock.
Venmax Drugs & Pharmaceuticals Stock Index Membership
See which indices include Venmax Drugs & Pharmaceuticals stock.
Check VENMAX index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Venmax Drugs & Pharmaceuticals Market Events Screener - Corporate Actions
Get Venmax Drugs & Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Venmax Drugs & Pharmaceuticals stock events that may affect VENMAX share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -26.93% | ||
| Annual General Meeting | NA | 0.00% | ||
| 2026-05-14 | 2026-05-14 | Quarterly Result Announcement | NA | 6.42% |
| 2026-02-07 | 2026-02-07 | Quarterly Result Announcement | NA | 14.82% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | 6.31% |
| 2025-07-23 | 2025-07-23 | Quarterly Result Announcement | NA | 13.02% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | 0.97% |
| 2025-02-08 | 2025-02-08 | Quarterly Result Announcement | NA | -2.05% |
| 2025-02-06 | 2025-02-06 | Extraordinary General Meeting | NA | 39.43% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | 0.00% |
Venmax Drugs & Pharmaceuticals Competitors Screener - Peer Comparison
Screen VENMAX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Venmax Drugs & Pharmaceuticals Company Announcements - News Screener
Screen VENMAX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Statement Of Deviation & Variation | - | |
| 2026-05-21 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-21 | Audited Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-21 | Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-13 | Board Meeting Intimation for Audited Standalone Financial Results Of The Company For The Quarter And Year Ended March 31 2026. | - |
| 2026-04-14 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-14 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-04-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-06 | Regulation 31(4) - SAST Disclosure | - |
| 2026-03-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-03-27 | Board Meeting Outcome for Modification Of Draft Scheme Of Amalgamation | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-03-23 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-03-11 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-07 | Statement Of Deviation And Variation For The Quarter Ended December 31 2025. | - |
| 2026-02-07 | Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025. | - |
| 2026-02-07 | Board Meeting Outcome for Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025. | - |
| 2026-01-30 | Board Meeting Intimation for Unaudited Financial Results Of The Company For The Quarter Ended December 31 2025. | - |
| 2026-01-21 | Conversion Of Share Warrants Into Equity | - |